Abstract
Monoclonal antibodies (mAbs) are an upcoming group of therapeutic compounds used to treat various types of diseases. Currently more than 100 mAbs are in clinical development. To establish the pharmacokinetic (PK) properties of mAbs many (pre-)clinica